著者

富田 隆 幸田 幸直 工藤 賢三

出版者

公益社団法人 日本薬学会

雑誌

YAKUGAKU ZASSHI (ISSN:00316903)

巻号頁・発行日

vol.138, no.3, pp.353-356, 2018-03-01 (Released:2018-03-01)

参考文献数

5

被引用文献数

1 4

---

For patients with dysphagia in medical facilities and nursing homes, food thickeners are routinely used to aid the ingestion of medicines such as tablets. However, some types of thickeners affect the disintegration and dissolution of tablets, such as rapidly-disintegrating magnesium oxide tablets and donepezil hydrochloride orally disintegrating tablets. Additionally, delayed disintegration and dissolution of tablets affect a drug's efficacy. As an example, with Voglibose orally disintegrating tablets, marked differences are observed in changes in glucose levels during glucose tolerance testing. When using food thickeners to aid tablet ingestion, it is therefore necessary to select a product that has little effect on drug disintegration, dissolution, and activity.

著者

富田 隆 後藤 英和 吉村 勇哉 坪内 良子 中西 利恵 小島 千賀子 米島 美穂子 吉田 正 田中 勝也 住谷 賢治 幸田 幸直

出版者

公益社団法人 日本薬学会

雑誌

YAKUGAKU ZASSHI (ISSN:00316903)

巻号頁・発行日

vol.135, no.6, pp.835-840, 2015-06-01 (Released:2015-06-01)

参考文献数

8

被引用文献数

11 17

---

It has been reported that magnesium oxide tablets are excreted in a non-disintegrated state in the stool of patients when the tablets are administered after being immersed in a food thickener. Therefore we examined whether immersion in a food thickener affects the pharmacological effect in patients taking magnesium oxide tablets, and whether immersion affects its disintegration and solubility. The mean dosage (1705 mg/d) was higher for patients who took tablets after immersion in a food thickener than for those who took non-immersed tablets (1380 mg/d). The disintegration time and dissolution rate of the immersed tablets were lower than those of non-immersed tablets in vitro. Furthermore, components that constitute the food thickener and differences in composition concentrations differentially affect the disintegration and solubility of magnesium oxide tablets. This suggests that commercially available food thickeners are likely to be associated with changes in the degradation of magnesium oxide tablets, and they therefore should be carefully used in certain clinical situations.

著者

石原 三也 本間 真人 久能 英子 渡邊 真知子 幸田 幸直

出版者

公益社団法人 日本薬学会

雑誌

YAKUGAKU ZASSHI (ISSN:00316903)

巻号頁・発行日

vol.122, no.9, pp.695-701, 2002-09-01 (Released:2003-02-18)

参考文献数

51

被引用文献数

22 19

---

The intestinal bacteria, Eubacterium sp. and Bifidobacterium sp., participate in the metabolism of active kampo-ingredients, glycyrrhizin (GL), sennoside (SEN) and baicalin (BL). Since antibiotics and bacterial preparations, Bifidobacterium longum (LAC-B®), Clostridium butyricum (MIYA-BM®), and Streptococcus faecalis (BIOFERMIN®), affect the bacterial population in intestinal bacterial flora, metabolism of the active kampo-ingredients in the bacterial flora may be altered by their combined administration. We investigated 1199 prescriptions including kampo-medicines for 308 patients. Combination use of kampo-medicines with antibiotics and bacterial preparations occurred with 7% and 10% of the kampo-prescription, respectively. Most antibiotics have activity against intestinal bacteria, except that cephems and macrolides are not active against to E. coli. This means that antibiotics may lower the metabolism of GL, SEN and BL when administered in combination. On the other hand, it is also highly possible that bacterial preparations increase the number of Eubacterium sp. and Bifidobacterium sp., resulting in enhanced metabolism of GL and SEN when they are used concomitantly with kampo-medicines. The present results suggested that the drug interactions of kampo-medicines with antibiotics and bacterial preparations should be confirmed in clinical studies.

著者

本間 真人 石原 三也 千 文 幸田 幸直

出版者

公益社団法人 日本薬学会

雑誌

YAKUGAKU ZASSHI (ISSN:00316903)

巻号頁・発行日

vol.126, no.10, pp.973-978, 2006 (Released:2006-10-01)

参考文献数

33

被引用文献数

19 32

---

Typical adverse effects of Shakuyaku-kanzo-To (SKT), an herbal medicine containing licorice, is a licorice-induced pseudoaldosteronism with hypokalemia and hypertension. The risk factors for this side effect are still unclear. To identify the risk factors, we surveyed 37 cases of licorice-induced pseudoaldosteronism in the literature and serum potassium levels in our patients receiving SKT and Shosaiko-To (SST), which contain 6 g and 1.5 g of licorice in the daily dose, respectively. In the case report survey, pseudoaldosteronism developed a median 35 (range 2—231) days after the administration of SKT, which is shorter than after SST (450, range 150—2190 days) and other licorice products including glycyrrhizin (210, range 14—730 days). A significant correlation was observed between the glycyrrhizin contents in the licorice preparations and the dosing periods for developing pseudoaldosteronism (r=-0.700, p < 0.01). A negative correlation was also observed between serum potassium level and dosing period for SKT, but not for SST. The difference in age (65.3 ± 11.6 vs. 57.2 ± 17.3 y) and dosing period (57.3 ± 66.3 vs. 19.0 ± 24.3 days) between the patients with and without hypokalemia after the administration of SKT was statistically significant (p < 0.05). The occurrence rate of hypokalemia including pseudoaldosteronism was around 80% with SKT administration for more than 30 days for patients exceeding 60 years old. It was suggested that patient age (>60 y) and dosing period of SKT (>30 days) might be risk factors for developing pseudoaldosteronism or hypokalemia as well as coadministration of drugs inducing hypokalemia.

著者

住谷 賢治 渡邊 真知子 本間 真人 馬場 泰行 猪股 伸一 豊岡 秀訓 幸田 幸直

出版者

一般社団法人 日本臨床薬理学会

雑誌

臨床薬理 (ISSN:03881601)

巻号頁・発行日

vol.33, no.1, pp.83S-84S, 2002-01-31 (Released:2010-06-28)

参考文献数

5

著者

富田 隆 後藤 英和 住谷 賢治 吉田 正 田中 勝也 幸田 幸直

出版者

公益社団法人 日本薬学会

雑誌

YAKUGAKU ZASSHI (ISSN:00316903)

巻号頁・発行日

vol.136, no.3, pp.517-521, 2016-03-01 (Released:2016-03-01)

参考文献数

9

被引用文献数

2 4

---

To avoid fluctuation of the serum lithium concentration (CLi), sodium chloride (NaCl) intake was regulated in oral alimentation. A 62-year-old woman was hospitalized and orally administered 400 mg of lithium carbonate a day to treat her mania. Her CLi was found to be 0.75-0.81 mEq/L. Vomiting made it difficult for the patient to ingest meals orally, and therefore parenteral nutrition with additional oral intake of protein-fortified food was initiated. On day 22, parenteral nutrition was switched to oral alimentation to enable oral intake of food. The total NaCl equivalent amount was decreased to 1.2 g/d, and the CLi increased to 1.15 mEq/L on day 26. Oral alimentation with semi-solid food blended in a mixer was immediately initiated. Although the total NaCl equivalent amount was increased to 4.5-5.0 g/d, her CLi remained high at 1.14-1.17 mEq/L on days 33 and 49, respectively. We investigated oral administration of NaCl (1.8 g/d) on day 52. The total NaCl equivalent amount was increased to 6.3-6.8 g/d, and the CLi decreased to 1.08-0.97 mEq/L on days 63 and 104, respectively. After the start of the orally administered NaCl, her diet was changed to a completely blended diet on day 125. The total NaCl equivalent amount was increased to 9.0-14.5 g/d, and the CLi decreased to 0.53 mEq/L on day 152; therefore, the oral administration of NaCl was discontinued on day 166. The CLi was found to be 0.70-0.85 mEq/L on days 176 and 220.

著者

高野 操 木下 節子 高橋 秀人 幸田 幸直 岡 慎一

出版者

一般社団法人 日本感染症学会

雑誌

感染症学雑誌 (ISSN:03875911)

巻号頁・発行日

vol.76, no.3, pp.203-211, 2002

被引用文献数

1

---

本研究は, 血友病/HIV-1感染者の長期的な予後と, 多剤併用療法に対する臨床効果を明らかにする目的で, 1990年から1993年時点に, 無症候期であった血友病/HIV-1感染者69人と, 非血友病/HIV-1感染者29人を対象に, 比較検討を行った.<BR>1990年-2000年までのCD4数の変化は, 両群に有意差を認めず, 観察開始からAIDSを死因とした生存時間にも, 両群に有意差を認めなかった. しかし, 血友病/HIV-1感染者におけるAIDS以外の死因として, 出血, 肝硬変・肝癌による死亡が特徴的にみられた.<BR>1997年以降の生存者は98人中55人 (血友病39人, 非血友病16人) で, そのうち多剤併用療法を導入した患者は, 血友病/HIV-1感染者28人, 非血友病/HIV-1感染者12人であった. SQVを除く初回多剤併用療法で, HIV-1RNA量を検出限界以下 (<400copies/m1) に抑制できた患者の割合は, 有意差を認めなかったが, 服薬継続期間は, 血友病/HIV-1感染者平均84週, 非血友病/HIV-1感染者平均51週で, 血友病/HIV-1感染者の方が有意に服薬継続期間が長かった (p<0.05). 一方, 多剤併用療法開始から, 2000年7月までの薬剤変更・中断歴を調べると, 血友病/HIV-1感染者の場合, 既に3回以上の変更が行われている患者が35.7%と, 非血友病/HIV-1感染者16.7%に比べ多い傾向を示した. このことから, 血友病/HIV-1感染者の間では, 頻回な治療変更を余儀なくされている患者群のある可能性が示唆された.

著者

高橋 昌也 新井 克明 本間 真人 鈴木 勝 佐藤 信一 幸田 幸直

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.28, no.2, pp.172-175, 2002-04-10 (Released:2011-03-04)

参考文献数

9

被引用文献数

2 1

---

To investigate the description of the expiration date and manufacturing number on the drug packages, “pillow” packages and “heat-seal” packages, the questionnairing was carried out to pharmaceutical companies. Fifty-six drugs consisting of three hundred thirty-seven items, with sales of over 10 billion yen in 1998, were investigated at the corresponding 26 companies. The recovery rate of the questionnaire from the company was 100%, and the answer for all questions was also perfect. Three hundred fourteen items (93%) have had description regarding the manufacturing number and/or the expiration date on the heat-sealed packages. The manufacturing number took precedence over the expiration date. Of 269 pillow packages, 69 items (26%) have had description of manufacturing number and/or expiration date on the pillow package. There were 41 products (12%) that the company did not guarantee an expiration date being described on the box container when the packages were taken out from the box container.As a result, the description of the manufacturing number and expiration date on the packages, “pillow” and “heat-seal”, is still not complete even though the companies guarantee the expiration date when the drugs were stored with these packages. Since the information of the expiration date is necessary for the appropriate management of tablet and capsule products, it is required to describe manufacturing number and expiration date on every drug package including “pillow” and “heat-seal” packages.

著者

本間 真人 田辺 正樹 小宅 典子 幸田 幸直

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.31, no.1, pp.77-80, 2005-01-10 (Released:2011-03-04)

参考文献数

10

被引用文献数

2 1

---

We report on a case of rhabdomyolysis induced by Shakuyaku-kanzo-To, a herbal medicine for spastic muscle pain. The patient was a 76-year-old female who received Shakuyaku-kanzo-To (TJ-68) and dichlofenac for lumbago. Fifteen weeks later, she was admitted to hospital because of liver dysfunction as determined from increases in AST, ALT and LDH. She was diagnosed with rhabdomyolysis due to marked elevation of CPK and myogloblin levels. The hypertension, hypokalemia and reduced renin and aldosterone levels that were also noted suggested that the rhabdomyolysis was associated with pseudoaldosteronism caused by the licorice extracts contained by Shakuyaku-kanzo-To. We confirmed that blood levels of glycyrrhetinic acid (257 ng/mL), a licorice component known to induce pseudoaldosteronism, were high and found the serum cortisone/cortisol ratio (O.09) to be low indicating reduced activity of 11 β-hydroxysteroid dehydrogenase, which catalyzes the conversion of cortisol to cortisone. The results we obtained suggested that blood glycyrrhetinic acid levels and cortisone/cortisol ratios could be used as diagnostic indicators for pseudoaldosteronism caused by herbal remedies containing licorice extracts.

著者

原田 康 垣内 祥宏 武田 光志 佐藤 信一 馬場 泰行 幸田 幸直

出版者

一般社団法人 日本医療薬学会

雑誌

病院薬学 (ISSN:03899098)

巻号頁・発行日

vol.25, no.4, pp.399-406, 1999-08-10 (Released:2011-08-11)

参考文献数

10

---

Recently, automatic tablet counting and packaging machines have come to be widely used for the one-dose packaging of tablets and capsules. However, coloration, i.e. changes in color, of such tablets repackaged by one-dose packaging machins for dispensing has been frequently observed in several kinds of tablets due to the light, humidity and temperature in the room. In this report, the changes observed over time in the controlled-release mesalazine product, Pentasa® tablets, repackaged with polyethylene-laminated cellophane and glassine films for the one-dose packaging was studied.The repackaged tablets changed color within a week at room conditions (22-25°C, 50-70% RH) under a 350 lux fluorescent white-1 amp ex posure for 12 h per day or in darkness. However, no coloration was observed for at least four weeks in a refrigerator (4°C, 20% RH) in dark ness. The weight of the repackaged tablets increased by about 1% at room conditions within a week, while no such weight increase in the tablets was observed while the tablets were kept in a refrigerator. No changes in the amounts of mesalazine and its degradates, gentigic acid and p-aminophenol, in the tablets were observed and the dissolution properties of mesalazine from the tablets also remained unchanged during the experimental period.Based on these findings, we conclude that the one-dose packaging of Pentasa® tablets is not a suitable procedure since it results in the absorption of moisture and changes in color.

著者

高橋 昌也 新井 克明 本間 真人 鈴木 勝 佐藤 信一 幸田 幸直

出版者

日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.28, no.2, pp.172-175, 2002

参考文献数

9

被引用文献数

2 1

---

To investigate the description of the expiration date and manufacturing number on the drug packages, "pillow" packages and "heat-seal" packages, the questionnairing was carried out to pharmaceutical companies. Fifty-six drugs consisting of three hundred thirty-seven items, with sales of over 10 billion yen in 1998, were investigated at the corresponding 26 companies. The recovery rate of the questionnaire from the company was 100%, and the answer for all questions was also perfect. Three hundred fourteen items (93%) have had description regarding the manufacturing number and/or the expiration date on the heat-sealed packages. The manufacturing number took precedence over the expiration date. Of 269 pillow packages, 69 items (26%) have had description of manufacturing number and/or expiration date on the pillow package. There were 41 products (12%) that the company did not guarantee an expiration date being described on the box container when the packages were taken out from the box container. As a result, the description of the manufacturing number and expiration date on the packages, "pillow" and "heat-seal", is still not complete even though the companies guarantee the expiration date when the drugs were stored with these packages. Since the information of the expiratioh date is necessary for the appropriate management of tablet and capsule products, it is required to describe manufacturing number and expiration date on every drug package including "pillow" and "heat-seal" packages.

著者

塚本 晶子 本間 真人 神林 泰行 木津 純子 幸田 幸直

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.33, no.8, pp.687-692, 2007 (Released:2009-09-04)

参考文献数

16

被引用文献数

5 4

---

One of the major adverse effects of Shakuyaku-kanzo-To (SKT),a herbal medicine containing licorice,is licoriceinduced pseudoaldosteronism with hypokalemia and hypertension.Owing to the risk of hypokalemia,caution should be therefore exercised when SKT is co-administered with potassium lowering drugs.In order to clarify this risk,we examined the occurrence of hypokalemia in 103 patients receiving SKT.Thirty (29.1%) of the 103 patients developed hypokalemia and SKT dosing periods tended to be longer in these patients than in those who did not develop hypokalemia (54.5 vs.23.0 days,respectively).The co-administration of potassium lowering drugs was more frequent in the patients with hypokalemia (90.0% vs.64.4% for no hypokalemia p<0.01).The occurrence rates of hypokalemia varied with drugs co-administered with SKT ; with 75.0% for glycyrrhizin preparations,47.2% for diuretics,41.9% for glucocorticoids,20.0% for sennoside preparations and 25.0% for others.The above results confirmed that the co-administration of potassium lowering drugs enhanced SKT-induced hypokalemia.Frequent serum potassium monitoring is therefore required when potassium lowering drugs,especially glycyrrhizin preparations,diuretics and glucocorticoids,are co-administered to patients receiving SKT.

著者

住谷 賢治 馬場 泰行 猪股 伸一 豊岡 秀訓 幸田 幸直

出版者

公益社団法人日本薬学会

雑誌

藥學雜誌 = Journal of the Pharmaceutical Society of Japan (ISSN:00316903)

巻号頁・発行日

vol.120, no.7, pp.652-656, 2000-07-01

参考文献数

17

被引用文献数

8

---

Orally-disintegrating tablets of clonidine hydrochloride, an α_2-adrenergic agonist, were prepared by the method of drying an aqueous suspension. The suspension was prepared using powdered lactose, and the composition ratio was 2 : 1 (powdered lactose : 0.048% clonidine hydrochloride solution). The suspension was dried under 4±1℃(72±15% R.H.). We obtained tablets containing clonidine hydrochloride (40μg/tablet). Physical properties of the tablets were as follows : hardness was 4.0 kgf, and disintegration time was 41.7 s (in vitro). In the clinical use, 8 patients, aged 1-2 year and weighing 9-11 kg, received approximately 4μg/kg body weight as clonidine hydrochloride. The tablet was administered 90 min before entering the operating room. All patients were willing to accept the tablet. The quality of separation from parents, sedation and a mask acceptance were excellent on all patients. These results suggest that the orally-disintegrating tablet of clonidine hydrochloride was useful in a clinical situation for the preanesthetic medication of pediatric patients aged 1-2 year.